Abstract
Allostery is a regulation at a distance by conveying information from one site to another and an intrinsic property of dynamic proteins. Allostery plays an essential role in receptor trafficking, signal transmission, controlled catalysis, gene turn on/off, or cell apoptosis. Allosteric mutations are considered as one of causes responsible for cancer development, leading to “allosteric diseases” by stabilizing an active or inactive conformation or changing the dynamic distribution of preexisting propagation pathways. The present article mainly focuses on the potential of allosteric therapies for lung cancer. Allosteric drugs may have several advantages over traditional drugs. The epidermal growth factor receptor mutations and signaling pathways downstream (such as PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways) were suggested to play a key role in lung cancer and considered as targets of allosteric therapy. Some allosteric inhibitors for lung cancer-specific targets and a series of preclinical trials of allosteric inhibitors for lung cancer have been developed and reported. We expect that allosteric therapies will gain more attentions to develop combinatorial strategies for lung cancer and metastasis.
Similar content being viewed by others
References
Di Paola, L., & Giuliani, A. (2015). Protein contact network topology: a natural language for allostery. Current Opinion in Structural Biology, 31, 43–48.
Nussinov, R., & Tsai, C. J. (2013). Allostery in disease and in drug discovery. Cell, 153(2), 293–305.
Tsai, C. J., Del Sol, A., & Nussinov, R. (2009). Protein allostery, signal trans- mission and dynamics: a classification scheme of allosteric mechanisms. Molecular Biosystems, 5(3), 207–216.
Changeux, J. P. (2012). Allostery and the Monod-Wyman-Changeux model after 50 years. Annual Review of Biophysics, 41, 103–133.
Collier, G., & Ortiz, V. (2013). Emerging computational approaches for the study of protein allostery. Archives Biochemistry and Biophysics, 538(1), 6–15.
Manley, G., & Loria, J. P. (2012). NMR insights into protein allostery. Archives Biochemistry and Biophysics, 519(2), 223–231.
Fenwick, R. B., Esteban-Martín, S., & Salvatella, X. (2014). The ensemble nature of allostery. Nature, 508(7496), 331–339.
Strickland, D., Moffat, K., & Sosnick, T. R. (2008). Light-activated DNA binding in a designed allosteric protein. Proceedings of the National Academy of Sciences of the United States of America, 105(31), 10709–10714.
Csermely, P., Palotai, R., & Nussinov, R. (2010). Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends in Biochemical Sciences, 35(10), 539–546.
Mittag, T., Kay, L. E., & Forman-Kay, J. D. (2010). Protein dynamics and conformational disorder in molecular recognition. Journal of Molecular Recognition, 23(2), 105–116.
Nussinov, R., Tsai, C. J., Xin, F., & Radivojac, P. (2012). Allosteric post-translational modification codes. Trends in Biochemical Sciences, 37(10), 447–455.
Ma, B., Tsai, C. J., Haliloğlu, T., & Nussinov, R. (2011). Dynamic allostery: linkers are not merely flexible. Structure, 19(7), 907–917.
del Sol, A., Tsai, C. J., Ma, B., & Nussinov, R. (2009). The origin of allosteric functional modulation: multiple pre-existing pathways. Structure, 17(8), 1042–1050.
Tsai, C. J., del Sol, A., & Nussinov, R. (2008). Allostery: absence of a change in shape does not imply that allostery is not at play. Journal of Molecular Biology, 378(1), 1–11.
Boehr, D. D., Nussinov, R., & Wright, P. E. (2009). The role of dynamic conformational ensembles in biomolecular recognition. Nature Chemical Biology, 5(11), 789–796.
Kar, G., Keskin, O., Gursoy, A., & Nussinov, R. (2010). Allostery and population shift in drug discovery. Current Opinion in Pharmacology, 10(6), 715–722.
Popovych, N., Sun, S., Ebright, R. H., & Kalodimos, C. G. (2006). Dynamically driven protein allostery. Nature Structural & Molecular Biology, 13(9), 831–838.
Urwyler, S. (2011). Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacological Reviews, 63(1), 59–126.
De Lean, A., Stadel, J. M., & Lefkowitz, R. J. (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta- adrenergic receptor. Journal of Biological Chemistry, 255(15), 7108–7117.
Keov, P., Sexton, P. M., & Christopoulos, A. (2011). Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology, 60(1), 24–35.
Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M., & Christopoulos, A. (2010). Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology, 35(4), 855–869.
Suratman, S., Leach, K., Sexton, P., Felder, C., Loiacono, R., & Christopoulos, A. (2011). Impact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. British Journal of Pharmacology, 162(7), 1659–1670.
Valant, C., Felder, C. C., Sexton, P. M., & Christopoulos, A. (2012). Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Molecular Pharmacology, 81(1), 41–52.
Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J. (2011). Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology, 60(1), 66–81.
Hall, D. A. (2000). Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Molecular Pharmacology, 58(6), 1412–1423.
Christopoulos, A., & Kenakin, T. (2002). G protein-coupled receptor allosterism and complexing. Pharmacological Reviews, 54(2), 323–374.
Nussinov, R., Tsai, C. J., & Ma, B. (2013). The underappreciated role of allostery in the cellular network. Annual Review of Biophysics, 42, 169–189.
Tzeng, S. R., & Kalodimos, C. G. (2011). Protein dynamics and allostery: an NMR view. Current Opinion in Structural Biology, 21(1), 62–67.
Popovych, N., Tzeng, S. R., Tonelli, M., Ebright, R. H., & Kalodimos, C. G. (2009). Structural basis for cAMP-mediated allosteric control of the catabolite activator protein. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 6927–6932.
Tzeng, S. R., & Kalodimos, C. G. (2009). Dynamic activation of an allosteric regulatory protein. Nature, 462(7271), 368–372.
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Evers, B. M. (2012). mTOR inhibitors in cancer therapy. Cancer Letters, 319(1), 1–7.
Goncharova, E. A. (2013). mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB Journal, 27(5), 1796–1807.
Geserick, C., Meyer, H. A., & Haendler, B. (2005). The role of DNA response elements as allosteric modulators of steroid receptor function. Molecular and Cellular Endocrinology, 236(1-2), 1–7.
Ma, B., Tsai, C. J., Pan, Y., & Nussinov, R. (2010). Why does binding of proteins to DNA or proteins to proteins not necessarily spell function? ACS Chemical Biology, 5(3), 265–272.
Garcia, H. G., Sanchez, A., Boedicker, J. Q., Osborne, M., Gelles, J., Kondev, J., & Phillips, R. (2012). Operator sequence alters gene expression independently of transcription factor occupancy in bacteria. Cell Reports, 2(1), 150–161.
Kim, S., Broströmer, E., Xing, D., Jin, J., Chong, S., Ge, H., Wang, S., Gu, C., Yang, L., Gao, Y. Q., Su, X. D., Sun, Y., & Xie, X. S. (2013). Probing allostery through DNA. Science, 339(6121), 816–819.
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013). Emerging paradigms in GPCR allostery: implications for drug discovery. Nature Reviews Drug Discovery, 12(8), 630–644.
Schelshorn, D., Joly, F., Mutel, S., Hampe, C., Breton, B., Mutel, V., & Lütjens, R. (2012). Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Molecular Pharmacology, 81(3), 309–318.
Foster, A. C., & Kemp, J. A. (2006). Glutamate- and GABA-based CNS therapeutics. Current Opinion in Pharmacology, 6(1), 7–17.
Lindberg, J. S., Culleton, B., Wong, G., Borah, M. F., Clark, R. V., Shapiro, W. B., Roger, S. D., Husserl, F. E., Klassen, P. S., Guo, M. D., Albizem, M. B., & Coburn, J. W. (2005). Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology, 16(3), 800–807.
Lieberman-Blum, S. S., Fung, H. B., & Bandres, J. C. (2008). Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clinical Therapeutics, 30(7), 1228–1250.
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011). Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. Journal of Clinical Investigation, 121(4), 1231–1241.
Lu, S., Li, S., & Zhang, J. (2014). Harnessing allostery: a novel approach to drug discovery. Medicinal Research Reviews, 34(6), 1242–1285.
Alamgeer, M., Ganju, V., & Watkins, D. N. (2013). Novel therapeutic targets in non-small cell lung cancer. Current Opinion in Pharmacology, 13(3), 394–401.
Li, T., Kung, H. J., Mack, P. C., & Gandara, D. R. (2013). Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. Journal of Clinical Oncology, 31(8), 1039–1049.
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J. S., Squire, J., Thunnissen, E., & Ladanyi, M. (2013). Molecular testing guideline for Selection of Lung Cancer Patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Molecular Diagnostics, 15(4), 415–453.
Hynes, N. E., & MacDonald, G. (2009). ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology, 21(2), 177–184.
Endres, N. F., Engel, K., Das, R., Kovacs, E., & Kuriyan, J. (2011). Regulation of the catalytic activity of the EGF receptor. Current Opinion in Structural Biology, 21(6), 777–784.
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 125(6), 1137–1149.
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011). Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Molecular Cell, 42(1), 9–22.
Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009). Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell, 137(7), 1293–1307.
Papakyriakou, A., Vourloumis, D., Tzortzatou-Stathopoulou, F., & Karpusas, M. (2009). Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation. Proteins, 76(2), 375–386.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129–2139.
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., & Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497–1500.
Gazdar, A. F. (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28(S1), S24–S31.
Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 11(3), 217–227.
Shan, Y., Eastwood, M. P., Zhang, X., Kim, E. T., Arkhipov, A., Dror, R. O., Jumper, J., Kuriyan, J., & Shaw, D. E. (2012). Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell, 149(4), 860–870.
Dixit, A., & Verkhivker, G. M. (2011). Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Computational Biology, 7(10), e1002179.
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research, 12(19), 5764–5769.
Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M., & Eck, M. J. (2008). The T790 mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 2070–2075.
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature Structural & Molecular Biology, 15(10), 1109–1118.
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 103–119.
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 8(8), 627–644.
Britten, C. D. (2013). PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemotherapy and Pharmacology, 71(6), 1395–1409.
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Malaponte, G., Mazzarino, M. C., Nicoletti, F., Libra, M., Maksimovic-Ivanic, D., Mijatovic, S., Montalto, G., Cervello, M., Laidler, P., Milella, M., Tafuri, A., Bonati, A., Evangelisti, C., Cocco, L., Martelli, A. M., & McCubrey, J. A. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2(3), 135–164.
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., Candido, S., Libra, M., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Cocco, L., Evangelisti, C., Chiarini, F., & Martelli, A. M. (2012). Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/ mTOR cascades which alter therapy response. Oncotarget, 3(9), 954–987.
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., Mazzarino, M. C., Fagone, P., Nicoletti, F., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Chiarini, F., Evangelisti, C., Cocco, L., & Martelli, A. M. (2012). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget, 3(10), 1068–1111.
Iida, M., Brand, T. M., Campbell, D. A., Starr, M. M., Luthar, N., Traynor, A. M., & Wheeler, D. L. (2013). Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy, 14(6), 481–491.
Holland, W. S., Chinn, D. C., Lara, P. N., Jr., Gandara, D. R., & Mack, P. C. (2015). Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. Journal of Cancer Research and Clinical Oncology, 141(4), 615–626.
Gadgeel, S. M., & Wozniak, A. (2013). Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clinical Lung Cancer, 14(4), 322–332.
Soria, J. C., Shepherd, F. A., Douillard, J. Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijevic, S., Di Scala, L., Gardner, H., Nogova, L., & Papadimitrakopoulou, V. (2009). Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology, 20(10), 1674–1681.
Price, K. A., Azzoli, C. G., Krug, L. M., Pietanza, M. C., Rizvi, N. A., Pao, W., Kris, M. G., Riely, G. J., Heelan, R. T., Arcila, M. E., & Miller, V. A. (2010). Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of Thoracic Oncology, 5(10), 1623–1629.
Ramalingam, S. S., Owonikoko, T. K., Behera, M., Subramanian, J., Saba, N. F., Kono, S. A., Gal, A. A., Sica, G., Harvey, R. D., Chen, Z., Klass, C. M., Shin, D. M., Fu, H., Sun, S. Y., Govindan, R., & Khuri, F. R. (2013). Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. Journal of Thoracic Oncology, 8(3), 369–372.
Besse, B., Leighl, N., Bennouna, J., Papadimitrakopoulou, V. A., Blais, N., Traynor, A. M., Soria, J. C., Gogov, S., Miller, N., Jehl, V., & Johnson, B. E. (2014). Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Annals of Oncology, 25(2), 409–415.
Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T. E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., & Tzekova, V. (2010). A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. Journal of Thoracic Oncology, 5(10), 1630–1636.
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., Smith, I., & Crinò, L. (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncology, 14(1), 38–47.
Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., Rasco, D., Jones, S. F., Smith, L., Cox, D. S., Durante, M., Bellew, K. M., Park, J. J., Le, N. T., & Tolcher, A. W. (2013). A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer, 49(9), 2077–2085.
Blumenschein, G. R., Jr., Smit, E. F., Planchard, D., Kim, D. W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M. J., Hanna, N. H., Kim, J. H., Mazieres, J., Kim, S. W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., & Jänne, P. A. (2015). A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Annals of Oncology, 26(5), 894–901.
Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H., Spano, J. P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., Pacey, S., Venturi, M., Kraeber-Bodéré, F., Tessier, J. J., Eberhardt, W. E., Paques, M., Guarin, E., Meresse, V., & Soria, J. C. (2014). Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clinical Cancer Research, 20(16), 4251–4261.
Honda, K., Yamamoto, N., Nokihara, H., Tamura, Y., Asahina, H., Yamada, Y., Suzuki, S., Yamazaki, N., Ogita, Y., & Tamura, T. (2013). Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 72(3), 577–584.
Acknowledgments
The work was supported by Zhongshan Distinguished Professor Grant (XDW), The National Nature Science Foundation of China (91230204, 81270099, 81320108001, 81270131, 81300010), The Shanghai Committee of Science and Technology (12JC1402200, 12431900207, 11410708600, 14431905100), Operation funding of Shanghai Institute of Clinical Bioinformatics, and Ministry of Education, Academic Special Science and Research Foundation for PhD Education (20130071110043).
Author information
Authors and Affiliations
Corresponding author
Additional information
Ye Ling and Meiling Jing authors contribute to the article equally as the first authorship
Ye Ling and Meiling Jing contributed equally to this work.
Rights and permissions
About this article
Cite this article
Ling, Y., Jing, M. & Wang, Xd. Allosteric therapies for lung cancer. Cancer Metastasis Rev 34, 303–312 (2015). https://doi.org/10.1007/s10555-015-9567-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-015-9567-z